Your results for

Filter by

Filter by
Results

Filter by

Content type
Key content topics
Key audience
Top cancer treatments

2-year relapse-free survival of 85% with no grade 3 toxicity

30/08/2016
/ Publications
/
Toxicity

A registry study of collective proton centres reported a 2-year relapse-free survival of 85% with no grade 3 toxicity occurred. Hodgkin lymphoma young survivors...

Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.

15/11/2022
/ Publications
/
IMPT
IMRT

Published in the Green Journal, the PTCOG lymphoma subcommittee conducted a systematic review on available dosimetric studies comparing IMPT free breathing (FB)...

Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.

16/01/2023
/ Publications

Published in the Red Journal, this study reported lymphopenia differences between IMRT and proton/carbon ion (PCIRT) for NSCLC. With data of 343 patients, this...

Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma - systematic review.

06/05/2024
/ Publications
/
Survival
Proton Reirradiation

This review included 11 studies representing a total of 529 patients. The findings include 1) the OS for 2 years varied from 91% - 98% for 5 of the included...

A bibliometric analysis of cardiotoxicity in cancer radiotherapy.

06/05/2024
/ Publications
/
Quality of life
Survival

Radiation induced heart disease (RIHD) significantly impacts the long-term survival and quality of life of cancer survivors as one of the most devastating...

Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory lymphoma: A PTCOG and PCG Collaboration.

16/01/2021
/ Publications
/
Toxicity

Symptomatic pneumonitis, a subacute toxicity, has an incidence of 17% to 24% (≥grade 2) even with IMRT. A total of 85 patients with r/r lymphoma (66% HL, 34%...

Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.

16/06/2021
/ Publications

This study reviewed 56 mediastinal lymphoma patients treated with proton therapy and reported that nearly all treated patients fit the International Lymphoma...